Should Men with a Rising PSA After Surgery Add Taxotere to Their Hormone Therapy?
A total of 413 relapsing prostate cancer patients whose PSA doubling time was less than nine (9) months and whose PSA was over 1.0 were evaluated. Half of the men were treated with Lupron and the other half received Lupron and Taxotere (docetaxel®). The study information is preliminary after only 2.5 years of follow-up but a statistical trend toward an improvement in cure rates was observed in men treated with Taxotere (docetaxel®) and Lupron.
The preceding abstract was presented at the 2015 meeting of the American Society of Clinical Oncology (ASCO) by Dr. Michael J. Morris of the Memorial Sloan Kettering Cancer Center in New York.
This entry was posted in 2015
. Bookmark the permalink